Company Performance Metrics
LeadArt Biotechnologies, a venture capital-backed biotech firm, is at the forefront of Chemoproteomics-driven drug discovery. Chemoproteomics data unveils the Mechanism of Action (MoA), off-targets, novel targets, and binding sites of phenotypically active molecules within living cells. Our company has developed a distinctive and robust
Chemoproteomics platform to accelerate drug discovery. We have constructed a one-of-a-kind probe library, featuring over 4,000 photoactive probes and more than 300 ABPP probes, with the capacity to label over 14,000 human proteins. Our achievements include the automation of chemoproteomics sample preparation, which is 100 times more efficient, and the facilitation of establishing large-scale protein-drug binding databases with high-quality data. Additionally, we have crafted a live-cell-based high-throughput screening platform, specifically tailored for ligand screening of any target, especially targets that pose significant challenges to conventional HTS (High Throughput Screening) and DEL (DNA-Encoded Library) screening methodologies.
